The IgA serological test is the most generally accepted NPC screening method, but the quantification of plasma EBV DNA originating from the tumor is a more sensitive biomarker for screening, as well as for predicting and detecting recurrent NPC disease. Here, CD79A is linked to nasopharyngeal carcinoma.